Beam Therapeutics (BEAM) Preferred Stock Liabilities (2019)
Beam Therapeutics' (BEAM) quarterly Preferred Stock Liabilities came in at $302.0 million in Q4 2019, up 1.1% on a QoQ basis from $298.8 million in Q3 2019.
Beam Therapeutics (BEAM) Preferred Stock Liabilities (2019) Analysis & Trends
Beam Therapeutics (BEAM) has 1 years of Preferred Stock Liabilities data on file, last reported at $302.0 million in Q4 2019.
- On a quarterly basis, Preferred Stock Liabilities changed N/A year-over-year to $302.0 million in Q4 2019; TTM through Dec 2019 was $302.0 million, a N/A change from a year earlier, with the FY2019 full-year figure at $302.0 million, changed N/A from the prior year.
- Preferred Stock Liabilities for Q4 2019 stood at $302.0 million, up from $298.8 million in the prior quarter.
- Over the last five years, Preferred Stock Liabilities for BEAM reached as high as $302.0 million in Q4 2019 and fell as low as $292.3 million in Q1 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Beam Therapeutics | 2.68 Bn | 2.68 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 302.05 Mn |
| Sep 30, 2019 | 298.75 Mn |
| Jun 30, 2019 | 295.52 Mn |
| Mar 31, 2019 | 292.30 Mn |